NEW YORK (GenomeWeb News) – French biotech Genoway said today it has licensed technology from Bluebird Bio to genetically modify rodents.
The license grants Genoway exclusive worldwide rights to Bluebird's RCME technology, which combines a recombinase system with genetic modification, enabling the introduction of a DNA sequence at a specific locus. The technology was developed at the Massachusetts Institute of Technology.
According to Genoway, based in Lyon, France, targeted insertion has now replaced most classic transgenic models, and RCME is an essential tool in the making of knock-in rodents.
Financial and other terms of the deal were not disclosed.
Bluebird develops gene therapies and has offices in Cambridge, Mass., and Paris. Genoway develops genetically modified and research models for the bio-pharmaceutical, chemical, agrochemical, and food industry.